Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction
- 1 January 1995
- journal article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 1 (2) , 145-151
- https://doi.org/10.1007/bf01062571
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Frequency of achieving optimal reperfusion with thrombolysis in acute myocardial infarction (analysis of four German multicenter studies)The American Journal of Cardiology, 1994
- Dose finding with a novel recombinant plasminogen activator (BM 06,022) in patients with acute myocardial infarction: Results of the German recombinant plasminogen activator studyJournal of the American College of Cardiology, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Anticoagulant effects of hirulog, ∗∗Hirulog™ brand direct thrombin inhibitor. a novel thrombin inhibitor, in patients with coronary artery diseaseThe American Journal of Cardiology, 1993
- Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarctionJournal of the American College of Cardiology, 1992
- Effectiveness of double bolus alteplase in the treatment of acute myocardial infarctionThe American Journal of Cardiology, 1991
- Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarctionThe American Journal of Cardiology, 1991
- Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1990
- Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1989
- Streptokinase in Recent Myocardial Infarction: A Controlled Multicentre TrialBMJ, 1971